OSR Holdings, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by OSR Holdings, Inc. (OSRH) on January 26, 2026. The report details the completion of a strategic acquisition by OSR Holdings Co., Ltd. (OSRK), a subsidiary of the Company.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the Company or the acquired entity. Financial statements and pro forma information for the acquired business are scheduled to be filed by amendment within 71 days of this report.
Material Changes
- Acquisition Completion: On January 26, 2026, OSRK completed a share exchange transaction to acquire 100% of Woori IO Co., Ltd. (WORIO), a South Korea-based medical device company specializing in non-invasive biosensing technology for glucose monitoring.
- Transaction Structure: WORIO became a wholly-owned subsidiary of OSRK. The acquisition was executed via the issuance of 84,338 newly issued shares of OSRK to former WORIO shareholders in exchange for 88,891 WORIO shares (exchange ratio of 0.948832 OSRK shares per WORIO share).
- Capital Impact: No shares of OSR Holdings, Inc. common stock were issued in connection with this transaction.
Outlook, Risks, and Management Commentary
Management announced the completion of the acquisition via a press release dated January 27, 2026, highlighting the securing of long-term shareholder alignment and a review of the strategic combination of medical device subsidiaries. The filing notes that detailed financial data is pending future amendment. No specific risks or contingencies regarding the transaction were detailed in this text beyond standard regulatory disclosures.
Investor Verification Checklist
- Verify the pending filing of financial statements and pro forma information for WORIO within the 71-day window.
- Review the full text of the press release (Exhibit 99.1) for details on the strategic combination of medical device subsidiaries.
- Confirm the impact of the 84,338 new OSRK shares on the subsidiary's capital structure and ownership dilution.
- Monitor future filings for integration plans and the commercial status of WORIO's non-invasive glucose monitoring technology.